Anti-inflammatory peptides and composition comprising the same
US-9540419-B2 · Jan 10, 2017 · US
Anti-inflammatory peptides and composition comprising the same
US12168039B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12168039-B2 |
| Application number | US-202318447049-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2023 |
| Priority date | May 11, 2012 |
| Publication date | Dec 17, 2024 |
| Grant date | Dec 17, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method of treating autoimmune disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating autoimmune disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1, wherein the autoimmune disease is thyroiditis, lupus, Goodpasture's syndrome, allograft rejection, graft versus host disease, or diabetes. 2. The method of claim 1 , wherein the composition is administered orally, rectally, transdermally, intravenously, intramuscularly, intraperitoneally, in the bone marrow, epidurally, or subcutaneously. 3. The method of claim 1 , wherein the composition comprises the isolated peptide at a concentration of 0.1 μg/mg to 1 mg/mg. 4. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg body weight of the subject. 5. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg body weight of the subject. 6. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day. 7. The method of claim 1 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1.0 g/kg body weight of the subject. 8. The method of claim 1 , wherein the peptide is administered 1 to 3 times daily.
Assignees
Inventors
Classifications
RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Peptides; Protein hydrolysates · CPC title
Inhibitors; Suppressors · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12168039B2 cover?
- The present invention relates to a method of treating autoimmune disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
- Who is the assignee on this patent?
- Gemvax & Kael Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).